Skip to content
10-Q

Quarterly Report

Nautilus Biotechnology, Inc. NAUT

0001808805-25-000042

← back to feed
Filed
Apr 29, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 24, 2025 126.15M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $33.24M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $27.65M
Current Liabilities Q1 2025 · Mar 31, 2025 $8.16M
Current Liabilities Q1 2025 · Dec 31, 2024 $7.63M
Total Liabilities Q1 2025 · Mar 31, 2025 $33.26M
Total Liabilities Q1 2025 · Dec 31, 2024 $34.01M
Current Assets Q1 2025 · Mar 31, 2025 $141.6M
Current Assets Q1 2025 · Dec 31, 2024 $132.83M
Total Assets Q1 2025 · Mar 31, 2025 $227.69M
Total Assets Q1 2025 · Dec 31, 2024 $242.74M
Shares Diluted Q1 2025 · Mar 31, 2024 125.14M sh
Capex Q1 2025 · Mar 31, 2024 $647K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$16.27M
Stockholders Equity Q1 2025 · Mar 31, 2024 $249.49M
Stockholders Equity Q1 2025 · Dec 31, 2023 $265.35M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.15
Eps Basic Q1 2025 · Mar 31, 2024 −$0.15
Rd Expense Q1 2025 · Mar 31, 2024 $12.93M
Net Income Q1 2025 · Mar 31, 2024 −$18.73M